<?xml version="1.0" encoding="ISO-8859-1"?>
<brand>
	<title><![CDATA[TAFINLAR]]></title>
	<colour><![CDATA[#00ccff]]></colour>
	<logo>tafinlar.png</logo>
	<rootVideo>brain_move_longer_1920.mov</rootVideo>
	<rootCaption>
		<copy><![CDATA[NOW LICENSED in monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation]]></copy>
		<footer><![CDATA[TAF SPC, p2, Section 4.1]]></footer>
	</rootCaption>

	<menu contentID="0">
		<!-- Break-3 Study Design -->
		<item id="0"><![CDATA[BREAK-3 STUDY DESIGN]]></item>
			<item id="0.0" contentID="0"><![CDATA[STUDY DESIGN OVERVIEW]]></item>
			<item id="0.1" contentID="0"><![CDATA[DR. HAUSCHILD ON BREAK-3 STUDY DESIGN VIDEO]]></item>
		
		<!-- Efficacy -->	
		<item id="1" contentID="0"><![CDATA[EFFICACY]]></item>
			<item id="1.0"  contentID="0"><![CDATA[BREAK-3 EFFICACY]]></item>
			<item id="1.1"  contentID="0"><![CDATA[DR. HAUSCHILD ON BREAK-3 EFFICACY (2011 DATA CUTOFF) VIDEO]]></item>
			<item id="1.2"  contentID="0"><![CDATA[DR. HAUSCHILD ON BREAK-3 EFFICACY (2012 FATA CUTOFF) VIDEO]]></item>
			
		<!-- Safety -->
		<item id="2" contentID="0"><![CDATA[SAFETY]]></item>
			<item id="2.0"  contentID="0"><![CDATA[SAFETY OVERVIEW]]></item>
			<item id="2.1"  contentID="0"><![CDATA[DR. HAUSCHILD ON BREAK-3 SAFETY VIDEO]]></item>
		
		<!-- Dosing -->	
		<item id="3" contentID="0"><![CDATA[DOSING]]></item>
			<item id="3.0"  contentID="0"><![CDATA[DOSING OVERVIEW]]></item>
		
		<!-- Break-MB Trial -->
		<item id="4" contentID="0"><![CDATA[BREAK-MB TRIAL]]></item>
			<item id="4.0"  contentID="0"><![CDATA[BREAK-MB TRIAL OVERVIEW]]></item>
			<item id="4.1"  contentID="0"><![CDATA[DR. ASCIERTO - BREAK-MB STUDY DESIGN VIDEO]]></item>
			<item id="4.2"  contentID="0"><![CDATA[DR. ASCIERTO - BREAK-MB IN COHORT A]]></item>
			<item id="4.3"  contentID="0"><![CDATA[DR. ASCIERTO - BREAK-MB IN COHORT B]]></item>
			<item id="4.4"  contentID="0"><![CDATA[DR. ASCIERTO - BREAK-MB SAFETY VIDEO]]></item>
			
		<!-- Mechanism of Action -->
		<item id="5" contentID="0"><![CDATA[MECHANISM OF ACTION]]></item>
			<item id="5.0"  contentID="0"><![CDATA[MOA OVERVIEW]]></item>
			<item id="5.1"  contentID="0"><![CDATA[MOA ANIMATION]]></item>
	</menu>
	
	<content>
		<content id="0" action="video-bg" videoID="taflinlar-root" cuePointSet="tafinlar-root" />
	</content>
	
	<videos>
		<video id="taflinlar-root" filename="brain_move_longer_1920.mov" loopInFrame="51" loopOutFrame="348" />
	</videos>
	
	<cuePointSets>
		<cuePointSet id="tafinlar-root">
			<cuePoint id="cue1" inFrame="60" outFrame="187" boxXY="49,272" boxWidth="321">
				<body><![CDATA[NOW LICENSED - TAFINLAR is indicated in monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation]]></body>
				<footer>GlaxoSmithKline. TAFINLAR Summary of Product Characteristics.</footer>
			</cuePoint>
			<cuePoint id="cue2" inFrame="212" outFrame="344" boxXY="49,272" boxWidth="321">
				<body><![CDATA[Before taking TAFINLAR, patients must have confirmation of tumour BRAFV600 mutation using a validated test]]></body>
				<footer>GlaxoSmithKline. TAFINLAR Summary of Product Characteristics.</footer>
			</cuePoint>
		</cuePointSet>
	</cuePointSets>
	
</brand>